Skip to results

Last updated date

Last updated date

Area of interest

Area of interest

Type (1 selected)

Type

Guidance programme (1 selected)

Guidance programme

Showing 651 to 675 of 758

Published guidance, NICE advice and quality standards
TitleReference numberPublishedLast updated
Botulinum toxin type A for the prevention of headaches in adults with chronic migraineTA260
Fingolimod for the treatment of highly active relapsing–remitting multiple sclerosisTA254
Pharmalgen for the treatment of bee and wasp venom allergyTA246
Tocilizumab for the treatment of rheumatoid arthritisTA247
Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy: Cetuximab (monotherapy or combination chemotherapy), bevacizumab (in combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapyTA242
Rituximab for the first-line treatment of stage III-IV follicular lymphomaTA243
Apixaban for the prevention of venous thromboembolism after total hip or knee replacement in adultsTA245
Bevacizumab and cetuximab for the treatment of metastatic colorectal cancerTA118
Tocilizumab for the treatment of systemic juvenile idiopathic arthritisTA238
Fulvestrant for the treatment of locally advanced or metastatic breast cancerTA239
Ticagrelor for the treatment of acute coronary syndromesTA236
Mifamurtide for the treatment of osteosarcomaTA235
Bortezomib and thalidomide for the first‑line treatment of multiple myelomaTA228
Dexamethasone intravitreal implant for the treatment of macular oedema secondary to retinal vein occlusionTA229
Agomelatine for the treatment of major depressive episodes (terminated appraisal)TA231
Myocardial perfusion scintigraphy for the diagnosis and management of angina and myocardial infarctionTA73
Erlotinib monotherapy for maintenance treatment of non-small-cell lung cancerTA227
Golimumab for the treatment of rheumatoid arthritis after the failure of previous disease-modifying anti-rheumatic drugsTA225
Rituximab for the first-line maintenance treatment of follicular non-Hodgkin's lymphomaTA226
Cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial diseaseTA223
Golimumab for the treatment of psoriatic arthritisTA220
Azacitidine for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemiaTA218
Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancerTA214
Bendamustine for the first-line treatment of chronic lymphocytic leukaemiaTA216
Aripiprazole for the treatment of schizophrenia in people aged 15 to 17 yearsTA213

Results per page

  1. 10
  2. 25
  3. 50
  4. All